Project Grant R61HL175113
- The National Heart Lung and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), awarded a $536,142 Project Grant to Saint Luke's Hospital of Kansas City to conduct the "Improving Quality in Cardiac Arrest via Resuscitation Academy Training: The IQ-CART Study". The grant aims to evaluate whether participation in the Resuscitation Academy training program is associated with improved survival rates for out-of-hospital cardiac arrest (OHCA) cases. The...
- The National Heart, Lung, and Blood Institute (NHLBI), through the Cardiovascular Diseases Research grant program (CFDA 93.837), awarded $793,956 to Resuscitation Innovations LLC, doing business as Advancedcpr Solutions LLC, for the project "HEAD UP CPR AND AORTIC OCCLUSION TO IMPROVE SURVIVAL AFTER REFRACTORY CARDIAC ARREST". This project grant, awarded on January 1, 2025 with a planned completion date of January 23, 2026, aims to develop and evaluate new treatments to improve...
- This federal Project Grant award from the National Heart, Lung, and Blood Institute (NHLBI), under the Cardiovascular Diseases Research program (CFDA 93.837), is focused on commercializing a novel Head-Up Position (HUP) CPR system to improve survival rates for out-of-hospital and in-hospital sudden cardiac arrest (SCA) patients. The $498,453 award supports Resuscitation Innovations LLC's efforts to optimize, manufacture, and validate the refined Elegard 3.0 device, which enables HUP CPR. This...
- The National Heart, Lung, and Blood Institute (NHLBI) awarded a $279,644 Project Grant under the Cardiovascular Diseases Research program (CFDA 93.837) to The Children's Hospital Corporation (doing business as Boston Children's Hospital) to study "Time to ROSC as a Novel Outcome for Pediatric Cardiac Arrest Trials." The project aims to develop new trial design techniques to enhance the feasibility of conducting high-quality randomized controlled trials for interventions to improve...
- This federal Project Grant award, provided by the National Heart, Lung, and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837), aims to apply state-of-the-art methods to evaluate the effectiveness of mechanical circulatory support (MCS) devices in treating acute myocardial infarction complicated by cardiogenic shock (AMI-CS). The $817,358 award, effective from August 19, 2025 to May 31, 2029, will support the following key activities: Appending individual patient...
- This $1,380,474 federal Project Grant awarded on September 24, 2025 by the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to improve the care of patients with acute heart and lung diseases. The University of Michigan will develop data-driven models to support improved decision-making for intensive care unit (ICU) triage and inpatient bed assignment. The project will identify determinants of triage and bed assignment, develop a clinical decision...
- This federal Project Grant award, valued at $272,226.00, was granted by the National Heart Lung and Blood Institute under the Cardiovascular Diseases Research program (CFDA 93.837). The project aims to determine how clinician and scheduling characteristics impact patient outcomes, and explore the moderating effect of patient characteristics on these relationships, for mechanically ventilated adults in intensive care units. The project will conduct a novel secondary analysis utilizing a unique...
- This federal Project Grant award of $889,188.00 from the National Heart Lung and Blood Institute, under the Cardiovascular Diseases Research program (CFDA 93.837), supports the development of a new oxygen therapy called Intravenous Oxygen (IVO2) for treating cardiac arrest. The project aims to optimize the molecular structure of polymeric microbubbles that can safely deliver high volumes of oxygen intravenously, without risks of embolism or vascular obstruction. This innovative approach is...
- This Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) provides $174,420 to The Trustees of the University of Pennsylvania to conduct research aimed at improving lung transplantation outcomes. The key objectives are to investigate the impact of centralizing deceased organ donor management at specialized Donor Care Units (DCUs) and assess the consequences for diverse stakeholders in the national donation and transplantation...
- This federal Project Grant award of $738,154 from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) aims to develop a novel mortality risk prediction model to accurately assess mortality risk for ICU patients across all patient groups. The key objectives are to: (1) identify mechanisms of systematic measurement error in commonly used ICU mortality risk prediction models, and (2) develop an accurate ICU mortality risk prediction model. The project will...
This $2,394,542 Project Grant award from the National Heart, Lung, and Blood Institute (CFDA 93.837 Cardiovascular Diseases Research) will fund a randomized controlled trial to test the effect of transferring patients resuscitated from out-of-hospital cardiac arrest to a specialty cardiac care center versus usual care. The study aims to: 1) estimate the impact of specialty cardiac care on functional recovery, 2) identify the minimum clinical and operational standards for specialty cardiac arrest centers, and 3) rigorously analyze the costs and benefits of transferring patients to specialty care. The grant was awarded to the University of Pittsburgh, which will conduct the trial in an optimal research environment to inform public policy and clinical practice for this high-mortality syndrome.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | $2.4m | 8/14/25 |